Free Daily Podcast Summary
OncLive On Air: Daily Summaries Delivered
by OncLive On Air
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 1 weeks ago56 min
S19 Ep17: Perioperative Research Success Is Set to Transform Bladder Cancer Care After ESMO 2026
In this episode of Oncology Unplugged, host Chandler Park, MD, MSc, FACP, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Petros Grivas, MD, PhD, FASCO, the medical director of local/regional outreach and international program and a professor in the Clinical Research Division at Fred Hutch Cancer Center, as well as a professor in the Division of Hematology and Oncology at the University of Washington School of Medicine in Seattle.Their discussion centered on key bladder cancer data presented at the 2026 ESMO Congress, highlighting the rapidly expanding landscape of perioperative, metastatic, and non–muscle-invasive disease management. Drs Park and Grivas first addressed findings from the phase 3 VOLGA trial (NCT04960709), which evaluated neoadjuvant durvalumab (Imfinzi) plus enfortumab vedotin-ejfv (Padcev), with or without tremelimumab (Imjudo), followed by cystectomy and adjuvant durvalumab in patients with cisplatin-ineligible or cisplatin-declining muscle-invasive bladder cancer. Dr Grivas noted that the durvalumab/enfortumab vedotin arm met both event-free survival (EFS) and overall survival (OS) end points, whereas the tremelimumab arm met the end point for EFS but not OS. He emphasized that the need for adjuvant enfortumab vedotin remains an open question.The conversation then turned to the discordant results among trials in cisplatin-eligible patients. Dr Grivas contrasted the positive phase 3 NIAGARA trial (NCT03732677) data with the results of the phase 3 KEYNOTE-866 (NCT03924856) and ENERGIZE (NCT03661320) trials, which did not meet their EFS end points, and noted that all 3 enfortumab vedotin–based perioperative trials were positive. They also discussed exploratory circulating tumor DNA analyses from VOLGA and the phase 3 KEYNOTE-B15 study (NCT04700124), molecular subtype analysis findings from NIAGARA, and ongoing bladder-preservation trials.Drs Park and Grivas also reviewed data in metastatic disease, including from cohort 7 of the phase 2 TROPHY-U-01 trial (NCT03547973), in which sacituzumab govitecan-hziy (Trodelvy) plus enfortumab vedotin and zimberelimab (AB122/GLS-010) yielded a high overall response rate. They also discussed data with sacituzumab tirumotecan (MK-2870/SKB264) plus pembrolizumab (Keytruda). In non–muscle-invasive disease, Dr Grivas discussed data from the phase 3 POTOMAC trial (NCT03528694) of durvalumab plus BCG and the role of shared decision-making in bladder cancer management. The experts concluded by highlighting developments in artificial intelligence, as well as the importance of patient advocacy and clinical trial participation.
- 1 weeks ago9 min
S19 Ep16: Thorough Treatment Adherence and Selection Anchor Proper TKI Utilization in CML
In our exclusive interview, Dr Haddad discussed the importance of consistent daily adherence to oral TKIs for achieving deep responses, treatment-free remission, and long-term survival in patients with CML. Additionally, he broke down common barriers to TKI adherence, including busy schedules, travel, and under-recognized adverse effects (AEs), underscoring the use of dose reductions and therapy changes to manage AEs and keep patients on treatment. Finally, Haddad explored where liquid and orally disintegrating TKI formulations, such as imatinib oral solution (Imkeldi), may help patients who cannot swallow, those with advanced-phase CML or Philadelphia chromosome–positive acute lymphoblastic leukemia, and pediatric patients.
- 1 weeks ago16 min
S19 Ep15: How Allergists Fit Into the Systemic Mastocytosis Management Equation
In today’s episode, we spoke with Nathan A. Boggs, MD, PhD, about the role the allergists play in the diagnosis and management of systemic mastocytosis. Dr Boggs is the director of the Allergy Division in the School of Medicine of Uniformed Services University of the Health Sciences in Bethesda, Maryland.In our exclusive interview, Dr Boggs broke down how allergists/immunologists fit into the multidisciplinary diagnosis and treatment of patients with systemic mastocytosis. Additionally, Boggs highlighted key strategies for symptom management and how agents such as avapritinib (Ayvakit), bezuclastinib (CGT9486), and elenestinib (BLU-263) have and will continue to affect the treatment paradigm.
- 1 weeks ago19 min
S19 Ep14: Board Review 2026: Top Hematology/Oncology Topics to Know
Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to deliver a board exam preparation guide for the days leading up to the American Board of Internal Medicine hematology and oncology certification exams, offering test-day strategies and a rapid-fire review of high-yield topics.The discussion began with exam logistics, noting back-to-back testing days on November 17 (hematology) and November 18 (oncology). Drs Armstrong and Tawagi encouraged examinees to use the exam blueprint to prioritize high-yield topics, such as gastrointestinal, breast, genitourinary, and lung cancers in oncology and neoplasms in hematology, and to prepare for the endurance required to read lengthy clinical vignettes.Regarding oncology content, they reviewed topics to know regarding stage II and III non–small cell lung cancer, including staging, perioperative immunotherapy regimens, driver-directed adjuvant therapy, and the clinical implications of the phase 3 PACIFIC trial (NCT02125461). They then covered high-yield breast cancer topics, such as HER2-positive regimens, the 21-gene recurrence score assay cutoffs, triple-negative adjuvant strategies, and use of PARP inhibitors in patients with BRCA mutations.For hematology, they emphasized the malignant hematologic conditions, hemoglobin electrophoresis, von Willebrand disease subtypes, and inherited bone marrow failure syndromes, including dyskeratosis congenita, Fanconi anemia, and Diamond-Blackfan anemia.Drs Armstrong and Tawagi also highlighted other testable areas, including black box warnings, clinical research methodology, ethics, performance status–guided decision-making, and supportive care. They concluded with wellness advice, cautioning against last-minute cramming, and recommended revisiting their prior board review episodes.
- 2 weeks ago21 min
S19 Ep13: Beyond PD-L1: Refining First-Line Treatment Decisions in Metastatic NSCLC
In this episode of OncLive On Air, Aditya Juloori, MD, a radiation oncologist and associate professor at the University of Chicago in Illinois, was joined by David Carbone, MD, PhD, a thoracic medical oncologist and director of the Thoracic Oncology Center at The Ohio State University in Columbus. Together, they explored how factors beyond PD-L1 expression, including histology, co-occurring genomic alterations, brain metastases, and patient fitness, can inform first-line regimen selection for patients with driver-negative metastatic non–small cell lung cancer (NSCLC).Dr Carbone began by explaining that immunotherapy has transformed the treatment landscape, with frontline regimens now producing an overall 5-year survival rate of approximately 20% and potentially curing a subset of patients. However, he noted that this benefit is not evenly distributed. Patients with PD-L1–negative disease tend to fare worse than those with PD-L1–positive tumors, and outcomes are particularly poor for patients with PD-L1–negative squamous disease. In the 5-year data from the phase 3 KEYNOTE-407 trial (NCT02775435), survival curves for this subgroup had fully converged with the control arm, and the 5-year survival rate among patients with PD-L1–negative nonsquamous disease in the phase 3 KEYNOTE-189 trial (NCT02578680) was below 10%.Drs Carbone and Juloori emphasized that dual checkpoint inhibition has emerged as an important option for these higher-risk populations. Dr Carbone highlighted that the CheckMate 9LA regimen (NCT03215706) of nivolumab (Opdivo) plus ipilimumab (Yervoy) with 2 cycles of chemotherapy produced a 5-year survival rate exceeding 20% in PD-L1–negative and squamous subsets, making it his preferred approach for patients with PD-L1–negative squamous disease. For PD-L1–negative nonsquamous tumors, he weighs additional factors such as brain metastases and STK11 or KEAP1 alterations. Although dual immunotherapy carries a higher risk of immune-related adverse effects, he noted that outcomes in CheckMate 9LA remained favorable even among patients who discontinued a component of therapy, underscoring the effectiveness of proactive toxicity management. He added that the chemotherapy-free regimen evaluated in the phase 3 CheckMate 227 trial (NCT02477826) demonstrated similar efficacy, and that many patients value receiving only 2 cycles of chemotherapy.The conversation also explored the management of patients with baseline brain metastases. Dr Juloori explained that in both CheckMate 227 and CheckMate 9LA, the benefit of dual immunotherapy was at least as large in patients with brain metastases as in those without. This may reflect the ability of CTLA-4 blockade to convert immunologically cold intracranial tumors, which tend to have fewer activated cytotoxic T cells and tertiary lymphoid structures, into more inflamed ones. He cited a phase 2 trial of ipilimumab, nivolumab, and chemotherapy that reported an intracranial response rate of approximately 50%. For patients with multiple asymptomatic brain metastases, Dr Juloori described starting the 9LA regimen with close monthly brain imaging to assess early intracranial response, an approach that can defer whole-brain radiation therapy and help preserve performance status and eligibility for subsequent therapies. He noted that some of his patients have avoided radiation for more than a year with sustained complete responses.Turning to genomic modifiers, Dr Carbone described STK11 and KEAP1 alterations as markers of immunologically cold, often PD-L1–negative tumors that may require more than standard chemotherapy plus pembrolizumab (Keytruda). The prospective phase 2 TRITON trial (NCT06008093) of durvalumab (Imfinzi) plus tremelimumab-actl (Imjudo) in STK11-, KEAP1-, or KRAS-mutant disease was limited by low accrual, but multiple studies support dual immunotherapy activity in these subsets. He cautioned, however, that mutation status is an imperfect surrogate for STK11 function, noting that his laboratory has identified mutant tumors that retain function and wild-type tumors that have lost it. As a result, he would still favor single-agent immunotherapy for a patient with high PD-L1 expression and an isolated STK11 mutation.Dr Carbone also addressed how to apply trial data to patients who are older, frail, or have reduced performance status. He suggested that limiting chemotherapy exposure may be particularly beneficial in these populations, while noting that patients with interstitial lung disease or active autoimmune conditions requiring aggressive immunosuppression may be poor candidates for dual immunotherapy. He added that age alone should not preclude more intensive treatment in patients with good performance status and organ function. Both experts expressed a preference for nivolumab plus ipilimumab over durvalumab plus tremelimumab, citing stronger
- 2 weeks ago25 min
S19 Ep12: Order Both IHC and NGS: Defining MET Alterations and Positioning Telisotuzumab Vedotin in Non–Small Cell Lung Cancer
In today’s episode, we spoke with Lyudmila Bazhenova, MD, and Sandip Patel, MD. Dr Bazhenova is a thoracic medical oncologist and co-lead of the lung cancer team at University of California San Diego Moores Cancer Center, and Dr Patel is a professor of medical oncology at UC San Diego.In our exclusive interview, Drs Bazhenova and Patel explained why describing a tumor as “MET positive” is no longer specific enough in non–small cell lung cancer (NSCLC). MET protein overexpression, MET exon 14 skipping mutations, and MET amplification are biologically distinct findings detected by different assays, and each carries its own treatment implications. Protein overexpression is identified by immunohistochemistry (IHC) on tumor tissue and defines eligibility for the antibody-drug conjugate (ADC) telisotuzumab vedotin-tllv (Emrelis), which is approved for the treatment of adult patients with locally advanced or metastatic, nonsquamous NSCLC harboring high c-MET protein overexpression who have received a prior systemic therapy; c-MET protein overexpression is defined as at least 3+ staining in 50% or more of tumor cells per IHC testing. Dr Patel noted that roughly 1 in 5 patients may harbor this target. MET exon 14 skipping mutations, found in approximately 2% to 4% of patients, are genomic alterations detectable by next-generation sequencing (NGS) on tissue or liquid biopsy and are treated with the MET inhibitors capmatinib (Tabrecta) or tepotinib (Tepmetko). Dr Bazhenova cautioned that DNA-based NGS can miss MET exon 14 skipping mutations, making RNA-based testing a valuable complement. MET amplification, which can arise de novo or as a resistance mechanism after third-generation EGFR inhibition, lacks a specific FDA-approved therapy, although Dr Patel described combining an EGFR inhibitor such as osimertinib (Tagrisso) with a MET inhibitor in the acquired-resistance setting.Because IHC and NGS measure different things, both experts order the 2 tests together rather than treating one as a substitute for the other. Dr Bazhenova likened NGS to examining a home’s blueprint and IHC to inspecting what was actually built, adding that high protein expression without a corresponding genomic alteration is not a discordant result. Dr Patel described sending liquid biopsy for genomic profiling alongside tissue so that limited tissue can be preserved for PD-L1, HER2, and MET IHC. When tissue is insufficient, he obtains a biopsy before second-line therapy, and he stressed documenting the exact aberration and score in the medical record so the finding can guide treatment years later. Dr Bazhenova also routinely repeats NGS and IHC at progression on EGFR-targeted therapy, since MET alterations are a common escape mechanism and acquired MET overexpression can emerge.The experts also addressed borderline IHC results and assay variability. Dr Patel noted that interpretation tends to be more consistent at high-intensity, high-percentage staining with the SP44 assay, and he encouraged direct conversations with pathologists and multidisciplinary tumor boards for cases near the cutoff. Dr Bazhenova highlighted data from the phase 2 LUMINOSITY trial (NCT03539536) showing activity in MET-intermediate tumors, defined as IHC 3+ staining in 25% to 50% of cells, with an overall response rate of 23% and a median duration of response of about 7 months, although this population falls outside the current label. She pointed to the ongoing phase 3 TeliMET NSCLC-01 trial (NCT04928846) comparing telisotuzumab vedotin with docetaxel in both MET-high and -intermediate disease, and recommended considering a repeat biopsy for patients near the threshold given tumor heterogeneity.On sequencing, Dr Patel described telisotuzumab vedotin as his standard of care for eligible patients after chemoimmunotherapy, citing a more favorable efficacy and toxicity profile than docetaxel, which yields a response rate of roughly 9%. He added that giving docetaxel first may blunt the benefit of a subsequent ADC with a similar mechanism. For patients with EGFR-mutant disease and acquired MET overexpression, Dr Bazhenova said she would favor datopotamab deruxtecan-dlnk (Datroway), noting that telisotuzumab vedotin produced a response rate of only about 16% in this group in LUMINOSITY. Looking ahead, she flagged payload-aware sequencing as a growing challenge, because many ADCs in development share a topoisomerase I inhibitor payload and trials often exclude patients previously exposed to that payload class, leaving little data to guide back-to-back use.
- 2 weeks ago22 min
S19 Ep11: Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
In today’s episode, we spoke with Triparna Sen, PhD, and Jacob Sands, MD. Dr Sen is a professor of internal medicine and the director of the Lung Cancer Preclinical Therapeutics Platform at the Ohio State University Comprehensive Cancer Center—James in Columbus. Dr Sands is associate chief of the Lowe Center for Thoracic Oncology and the oncology medical director of the International Patient Center at Dana-Farber Cancer Institute, as well as an assistant professor at Harvard Medical School in Boston, Massachusetts.In our exclusive interview, Drs Sen and Sands discussed findings from the phase 3 IMforte trial (NCT05091567), which showed that adding lurbinectedin (Zepzelca) to atezolizumab (Tecentriq) maintenance following carboplatin, etoposide, and atezolizumab induction improved outcomes in patients with extensive-stage small cell lung cancer (SCLC). Dr Sen noted that although the regimen’s safety profile was manageable, the combination does increase rate of hematologic toxicities, including anemia, neutropenia, and thrombocytopenia, so the key question is whether the added treatment burden is justified by longer disease control and survival. Dr Sands added that the neutropenia rates in IMforte were lower than in the earlier second-line lurbinectedin experience, likely because primary prophylaxis, such as granulocyte colony-stimulating factor, was permitted.The experts also weighed in on a trial in progress presented at the 2026 World Conference on Lung Cancer evaluating lurbinectedin plus durvalumab (Imfinzi) as maintenance therapy. Dr Sen explained that a positive result could show that the strategy is reproducible with a different PD-L1 inhibitor and induction regimen but cautioned against assuming a class-wide effect or treating the 2 regimens as interchangeable. Dr Sands said he would not expect durvalumab to perform differently from atezolizumab in this context, and that the more pressing question is whether lurbinectedin belongs in maintenance at all, particularly as the IMforte curves have converged with longer follow-up. Both experts pointed to the phase 3 DeLLphi-305 trial (NCT06211036) of tarlatamab (Imdelltra) plus durvalumab vs durvalumab alone as first-line maintenance, which has reported positive OS and PFS results via press release, as the most significant development to watch in this space.Turning to the relapsed setting, Drs Sen and Sands discussed the negative phase 3 LAGOON trial (NCT05153239), in which neither lurbinectedin monotherapy nor lurbinectedin plus irinotecan improved OS vs investigator’s choice of topotecan (Hycamtin) or irinotecan, leading to the withdrawal of lurbinectedin’s second-line indication. Dr Sands highlighted that the control arm median OS was unexpected given the median OS data that supported the original accelerated approval of the agent. Both experts emphasized that the LAGOON results should not be conflated with the maintenance data, and Dr Sands expressed hope that lurbinectedin remains a guideline-listed option in later lines, citing its convenient every-3-week dosing.Finally, the experts looked ahead to emerging therapies. Dr Sands discussed B7-H3–directed antibody-drug conjugates (ADCs), including YL201 and ifinatamab deruxtecan. He also outlined practical toxicity management for ADCs, including cytopenias, nausea, fatigue, alopecia counseling, and the challenge of distinguishing drug-related interstitial lung disease from waxing and waning inflammatory findings common in SCLC. Dr Sen highlighted anticipated data at the 2026 ESMO Congress and stressed that treatment selection in SCLC maintenance will depend on magnitude of benefit, patient selection, toxicity, and center capabilities rather than a one-size-fits-all approach.
- 3 weeks ago10 min
S19 Ep10: FDA Approval Insights: First-Line Maintenance Tucatinib/Trastuzumab/Pertuzumab in Advanced HER2+ Breast Cancer
In today’s episode, we spoke with Erika P. Hamilton, MD, about the FDA approval of tucatinib (Tukysa) plus trastuzumab (Herceptin) and pertuzumab (Perjeta) for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer following induction therapy. Dr Hamilton is director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute.This regulatory decision was backed by data from the phase 3 HER2CLIMB-05 trial (NCT05132582), in which treatment with tucatinib plus trastuzumab and pertuzumab generated a median progression-free survival of 24.9 months (95% CI, 21.3-not reached) vs 16.3 months (95% CI, 12.6-18.7) with placebo, translating to a 35.9% reduction in the risk of disease progression or death (HR, 0.64; 95% CI, 0.51-0.80; 2-sided P < .0001).In our exclusive interview, Dr Hamilton highlighted the significance of this approval, key data from HER2CLIMB-05, and potential next steps for the HER2-positive breast cancer treatment paradigm.
Get OncLive On Air summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Podcasts in similar categories.
The Jamie Kern Lima Show
Entrepreneur Jamie Kern Lima interviews experts and celebrities about overcoming self-doubt and building self-belief.
The Dr. John Delony Show
A therapist answers callers' questions about relationships, mental health, and personal struggles with practical advice.
The Mel Robbins Podcast
A motivational podcast offering research-backed tools and personal stories to help listeners make positive life changes.
We're Out of Time
Discusses the fentanyl crisis, mental health, and resilience through interviews with recovery experts, survivors, and public figures.
Biohack-it
A weekly exploration of biohacking, holistic health, and science-driven strategies for optimizing physical and mental well-being.
Tony Mantor: Why Not Me ?
Explores autism, mental health, and human stories to promote understanding, challenge stigma, and support neurodiversity.
Inside AsembleAI: DeepTech, AI & Science
Experts discuss AI's impact on business, product development, and leadership with researchers, founders, and executives.
Nothing much happens: bedtime stories to help you sleep
Soothing bedtime stories told twice, slowly, to help ease racing thoughts and guide listeners into sleep.
About OncLive On Air
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from OncLive On Air in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's OncLive On Air daily summary?
It's a free AI-powered email that summarizes new episodes of OncLive On Air as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the OncLive On Air podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official OncLive On Air product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by OncLive On Air.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts, any in the catalog. Basic raises that to 15, Pro to 40 and Max to 100. Browse our full catalog at /podcasts.
How often does OncLive On Air release new episodes?
OncLive On Air publishes daily. Our AI generates a summary within hours of each new episode.
What topics does OncLive On Air cover?
OncLive On Air covers topics including Science, Fitness, Health & Fitness. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting OncLive On Air summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.